News
Important Only
Other
Three people reported killed and dozens wounded near aid site in Gaza, medics say
Report is the latest to underscore volatile security situationIsrael says aware of reports of casualties and investigatingGaza Humanitarian Foundation says aid distributed without incidentPrivate, U.S.-backed aid group has been criticised by UNGaza health ministry says 51 killed across enclave in pa...Reuters
Mon, Jun 2
Other
Sanofi Exercises License Extension Option To Nurix’S Stat6 Program
June 2 (Reuters) - Nurix Therapeutics Inc NRIX.O:SANOFI EXERCISES LICENSE EXTENSION OPTION TO NURIX’S STAT6 PROGRAMNURIX THERAPEUTICS INC - ELIGIBLE FOR $465 MILLION IN MILESTONES AND ROYALTIESNURIX THERAPEUTICS INC - TO RECEIVE $15 MILLION LICENSE EXTENSION FEE FROM SANOFIReuters
Mon, Jun 2
Forex
USD/CHF sinks to six-week low as strong Swiss GDP, softer Retail Sales boost Swiss Franc
The Swiss Franc (CHF) extends its winning streak against the US Dollar (USD) for the third consecutive day on Monday, starting the week on a firm footing as a broadly weak US Dollar and cautious global sentiment continue to underpin demand for the safe-haven currency.
Fxstreet
Mon, Jun 2
Other
Imdelltra Significantly Reduced Risk Of Death By 40% In Small Cell Lung Cancer Patients
June 2 (Reuters) - Amgen Inc AMGN.O:IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTSAMGEN INC - IMDELLTRA SHOWS SURVIVAL ADVANTAGE OVER STANDARD CHEMOTHERAPYAMGEN INC - IMDELLTRA EXTENDS MEDIAN OVERALL SURVIVAL TO 13.6 MONTHSReuters
Mon, Jun 2
Other
Color Star Technology Encourages To Disregard Unauthorized May 30 Filing In Entirety As It Relates To CEO Position
June 2 (Reuters) - Color Star Technology Co Ltd ADD.O:COLOR STAR TECHNOLOGY- ENCOURAGES TO DISREGARD UNAUTHORIZED MAY 30 FILING IN ENTIRETY AS IT RELATES TO CEO POSITIONCOLOR STAR -CONDUCTING INTERNAL INVESTIGATION INTO CIRCUMSTANCES SURROUNDING UNAUTHORIZED MAY 30 FILINGSource text: [ID:n0001213900...Reuters
Mon, Jun 2
Other
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis
June 2 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS INITIATES PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITISACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026Reuters
Mon, Jun 2
Other
JPMorgan CEO Jamie Dimon tells Fox Business US debt could cause bond turmoil
NEW YORK, June 2 (Reuters) - JPMorgan Chase JPM.N CEO Jamie Dimon said on Monday that the rising U.S. national debt is going to create a "tough time" for the bond market and could eventually cause spreads to widen, he told Fox Business’ "Mornings with Maria" program.Reuters
Mon, Jun 2
Other
Lilly Presents First Clinical Data For Its Investigational, Next-Generation Frα
June 2 (Reuters) - Eli Lilly and Co LLY.N:LILLY PRESENTS FIRST CLINICAL DATA FOR ITS INVESTIGATIONAL, NEXT-GENERATION FRΑ TARGETING ADC IN PLATINUM-RESISTANT OVARIAN CANCER AT THE 2025 ASCO ANNUAL MEETINGELI LILLY AND CO - PRELIMINARY ORR OF 55% AT 4 MG/KG DOSEReuters
Mon, Jun 2
